Alternative capsid strategies for targeting recombinant AAV gene therapy

Gene Therapy and Regulation

Volumn 2, Issue 2, 2004, Pages 139-148

  Loiler, Scott A ^a   Flotte, Terence R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Diabetes; Gene therapy; Targeting

Indexed keywords

APOLIPOPROTEIN E; PARVOVIRUS VECTOR;

DIABETES MELLITUS; DNA INTEGRATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SEROTYPE; TARGET CELL; TARGET ORGAN; TISSUE GROWTH; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; PARVOVIRUS;

EID: 1342281622     PISSN: 13889532     EISSN: None     Source Type: Journal    
DOI: 10.1163/156855803322664628     Document Type: Review

References (48)

1. Alisky, J.M., Hughes, S.M., Sauter, S.L., Jolly, D., Dubensky, T.W., Jr., Staber, P.D., Chiorini, J.A. and Davidson, B.L. (2000). Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport, 11: 2669-2673.
2. Ardelt, P.U., Wood, C.G., Chen, L., Mintz, P.J., Moya, C., Arap, M.A., Wright, K.C., Pasqualini, R. and Arap, W. (2003). Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. J. Urol., 169: 1535-1540.
3. Auricchio, A., O'Connor, E., Weiner, D., Gao, G.P., Hildinger, M., Wang, L., Calcedo, R. and Wilson, J.M. (2002). Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J. Clin. Invest., 110: 499-504.
4. Bartlett, J.S., Kleinschmidt, J., Boucher, R.C. and Samulski, R.J. (1999). Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat. Biotechnol., 17: 181-186.
5. Beck, S.E., Jones, L.A., Chesnut, K., Walsh, S.M., Reynolds, T.C., Carter, B.J., Askin, F.B., Flotte, T.R. and Guggino, W.B. (1999). Repeated delivery of adeno-associated virus vectors to the rabbit airway. J. Virol., 73: 9446-9455.
6. Berns, K.I. (1990). Parvovirus replication. Microbiol. Rev., 54: 316-329.
7. Buchen-Osmond, C. (2003). ICTVdB Management, The Earth Institute, Biosphere 2 Center, Oracle, AZ, USA.
8. Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R.J. and Walsh, C.E. (2000). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther., 2: 619-623.
9. Chapman, M.S. and Rossmann, M.G. (1993). Structure, sequence, and function correlations among parvoviruses. Virology, 194: 491-508.
10. Chiorini, J.A., Afione, S. and Kotin, R.M. (1999). Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes. J. Virol., 73: 4293-4298.
11. Davidoff, A.M., Ng, C.Y., Zhou, J., Spence, Y. and Nathwani, A.C. (2003). Gender significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood, prepublished online March 13, 2003.
12. Douar, A.M., Poulard, K., Stockholm, D. and Danos, O. (2001). Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol., 75: 1824-1833.
13. Duan, D., Yue, Y., Yan, Z., Yang, J. and Engelhardt, J.F. (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest., 105: 1573-1587.
14. Duan, D., Yan, Z., Yue, Y., Ding, W. and Engelhardt, J.F. (2001). Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J. Virol., 75: 7662-7671.
15. Flotte, TR., Solow, R., Owens, R.A., Afione, S., Zeitlin, P.L. and Carter, B.J. (1992). Gene expression from adeno-associated virus vectors in airway epithelial cells. Am. J. Respir. Cell Mol. Biol., 7: 349-356.
16. Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA, 99: 11854-11859.
17. Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deleage, G. and Hallek, M. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med., 5: 1052-1056.
18. Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R. and Weitzman, M.D. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther., 3: 964-975.
19. Halbert, C.L., Allen, J.M. and Miller, A.D. (2001). Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol., 75: 6615-6624.
20. Hauck, B. and Xiao, W. (2003). Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol., 77: 2768-2774.
21. Hauck, B., Chen, L. and Xiao, W. (2003). Generation and characterization of chimeric recombinant AAV vectors. Mol. Ther., 7: 419-425.
22. Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'Malley, K.L. and During, M.J. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet., 8: 148-154.
23. Kessler, P.D., Podsakoff, G.M., Chen, X., McQuiston, S.A., Colosi, P.C., Matelis, L.A., Kurtzman, G.J. and Byme, B.J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA, 93: 14082-14087.
24. Loiler, S.A., Conlon, T.J., Song, S., Tang, Q., Warrington, K.H.J., Agarwal, A., Kapturczak, M., Li, C., Ricordi, C., Atkinson, M.A., Muzyczka, N. and Flotte, T.R. (2003). Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Therapy, 10: 1551-1558.
25. Maruta, F., Parker, A.L., Fisher, K.D., Hallissey, M.T., Ismail, T., Rowlands, D.C., Chandler, L.A., Kerr, D.J. and Seymour, L.W. (2002). Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther., 9: 543-552.
26. Mastakov, M.Y., Baer, K., Symes, C.W., Leichtlein, C.B., Kotin, R.M. and During, M.J. (2002). Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol., 76: 8446-8454.
27. Muster, C.J., Lee, Y.S., Newbold, J.E. and Leis, J. (1980). Physical mapping of adeno-associated virus serotype 4 DNA. J. Virol., 35: 653-661.
28. Nakamura, G.R., Reynolds, M.E., Chen, Y.M., Starovasnik, M.A. and Lowman, H.B. (2002). Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor. Proc. Natl. Acad. Sci. USA, 99: 1303-1308.
29. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M. and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther., 4: 174-181.
30. Pajusola, K., Gruchala, M., Joch, H., Luscher, T.F., Yla-Herttuala, S. and Bueler, H. (2002). Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J. Virol., 76: 11530-11540.
31. Perabo, L., Buning, H., Girod, A., Ried, M., Kofler, D., Enssle, J. and Hallek, M. (2002). Adeno-associated virus display: a combinatorial library for the generation of retargeted vectors. Mol. Ther., 5: S303.
32. Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J.A. and Castillas, M., Jr. (2002). Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol., 76: 12900-12907.
33. Rabinowitz, J.E., Xiao, W. and Samulski, R.J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology, 265: 274-285.
34. Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X. and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol., 76: 791-801.
35. Ried, M.U., Girod, A., Leike, K., Buning, H. and Hallek, M. (2002). Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J. Virol., 76: 4559-4566.
36. Rutledge, E.A., Halbert, C.L. and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol., 72: 309-319.
37. Samulski, R.J., Srivastava, A., Berns, K.I. and Muzyczka, N. (1983). Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell, 33: 135-143.
38. Sanlioglu, S., Monick, M.M., Luleci, G., Hunninghake, G.W. and Engelhardt, J.F. (2001). Rate limiting steps of AAV transduction and implications for human gene therapy. Curr. Gene Ther., 1: 137-147.
39. Shadidi, M. and Sioud, M. (2003). Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. Faseb J., 17: 256-258.
40. Shi, W., Arnold, G.S. and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther., 12: 1697-1711.
41. Snyder, R.O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winther, B., Meuse, L., Cohen, L.K., Thompson, A.R. and Kay, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet., 16: 270-276.
42. Tam, S.P., Zhang, X. and Koschinsky, M.L. (1996). Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J. Lipid Res., 37: 518-533.
43. Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T. and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol., 74: 8635-8647.
44. Xiao, W., Chirmule, N., Berta, S.C., McCullough, B., Gao, G. and Wilson, J.M. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol., 73: 3994-4003.
45. Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A. and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA, 99: 10405-10410.
46. Yan, Z., Zak, R., Luxton, G.W., Ritchie, T.C., Bantel-Schaal, U. and Engelhardt, J.F. (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol., 76: 2043-2053.
47. Yang, Q., Mamounas, M., Yu, G., Kennedy, S., Leaker, B., Merson, J., Wong-Staal, F., Yu, M. and Barber, J.R. (1998). Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther., 9: 1929-1937.
48. Zhang, H.G., Xie, J., Dmitriev, I., Kashentseva, E., Curiel, D.T., Hsu, H.C. and Mountz, J.D. (2002). Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production. J. Virol., 76: 12023-12031.